Sequencing results in such patients have revealed the presence of heterogeneous TET2 mutations in 12–26% of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). This evidence concerns the gene TET2 and myelodysplastic syndrome.